Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN

Delayed Quote. Delayed  - 07/27 10:00:00 pm
415.09 USD   +4.22%
07/18 REGENERON PHARM : Announces Upcoming 2016 Investor Conference Presen..
07/13 REGENERON PHARM : Announces 2016 Winners of the Prize for Creative I..
07/12 REGENERON PHARM : Award-Winning Chef Elizabeth Falkner Reveals Her S..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Regeneron: Sanofi Plans to Increase Stake to Over $500 Million of Stock

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2013 | 04:44pm CEST
   By Melodie Warner 
 

Regeneron Pharmaceuticals Inc. (>> Regeneron Pharmaceuticals Inc) said Sanofi S.A. (SNY, SAN.FR) notified the biopharmaceutical company of its intent to boost its investment in the company and push its ownership of voting securities to more than $500 million.

Sanofi currently holds about 17% of Regeneron's shares outstanding, according to FactSet Research.

Regeneron said a December 2007 investor agreement bonds the French drug maker to certain standstill provisions, including an agreement not to acquire more than 30% of Regeneron's Class A stock and common stock outstanding.

Regeneron said these standstill provisions are in effect until the fifth anniversary of the expiration of a license and collaboration agreement between the companies.

Sanofi and Regeneron have worked together on experimental cancer drug Zaltrap, among other things.

Shares of Regeneron rose 5.6% to $175.13 in recent trading and have climbed 24% in the past three months.

Write to Melodie Warner at melodie.warner@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Regeneron Pharmaceuticals Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
07/21 REGENERON PHARMACEUTICALS : Patent Issued for Isolating Cells Expressing Secrete..
07/21 REGENERON PHARMACEUTICALS : Assigned Patent
07/18 REGENERON PHARMACEUTICALS : Announces Upcoming 2016 Investor Conference Presenta..
07/15 REGENERON PHARMACEUTICALS : Patent Issued for Methods of Producing Hybrid Antibo..
07/14 REGENERON PHARMACEUTICALS : Patent Issued for Methods of Producing Hybrid Antibo..
07/14 REGENERON PHARMACEUTICALS : and Sanofi Announce Approval of Praluent® alirocumab..
07/14 REGENERON PHARMACEUTICALS : Assigned Patent
07/13 REGENERON PHARMACEUTICALS : Announces 2016 Winners of the Prize for Creative Inn..
07/12 REGENERON PHARMACEUTICALS : Award-Winning Chef Elizabeth Falkner Reveals Her Str..
07/08 REGENERON PHARMACEUTICALS : to Report Second Quarter 2016 Financial and Operatin..
More news
Sector news : Bio Therapeutic Drugs
07/27DJVERTEX PHARMACEUTICALS : Pharma Loss Narrows as Cystic Fibrosis Drug Sales Grow
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised
07/27DJAMGEN : Profit Rises 13%, 2016 Outlook Raised -- Update
07/27DJAmgen Profit Rises 13%, 2016 Outlook Raised
07/27 GSK chases next biotech asthma drug with 175 million pounds J&J deal
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
07/27 Investing In Biotech And The Internet Of Things (Podcast With Dana Blankenhor..
07/25 Is Biotech Finally Ready To Move Higher?
07/25 RETIREMENT STRATEGY : 5 Pharmaceutical Dividends To Buy Here
07/22 Re-Evaluation Of LDL Cholesterol-Level Impacts Could Benefit Amarin's Vascepa
07/22 BIOGEN BEATS, RAISES : Bye, Bye Bear Move, Hello Bull?
Advertisement
Financials ($)
Sales 2016 5 094 M
EBIT 2016 1 840 M
Net income 2016 676 M
Finance 2016 1 428 M
Yield 2016 -
P/E ratio 2016 72,38
P/E ratio 2017 44,54
EV / Sales 2016 7,94x
EV / Sales 2017 6,39x
Capitalization 41 850 M
More Financials
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Technical analysis trends REGENERON PHARMAC...
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 468 $
Spread / Average Target 18%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Neil Stahl Executive VP-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTIC..-27.26%41 850
AMGEN, INC.3.29%125 957
GILEAD SCIENCES, INC.-19.90%107 944
CELGENE CORPORATION-11.34%82 247
VERTEX PHARMACEUTICALS..-24.52%23 493
ACTELION LTD23.35%19 965
More Results